MX2024011668A - Inmunosupresion especifica del antigeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1. - Google Patents

Inmunosupresion especifica del antigeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1.

Info

Publication number
MX2024011668A
MX2024011668A MX2024011668A MX2024011668A MX2024011668A MX 2024011668 A MX2024011668 A MX 2024011668A MX 2024011668 A MX2024011668 A MX 2024011668A MX 2024011668 A MX2024011668 A MX 2024011668A MX 2024011668 A MX2024011668 A MX 2024011668A
Authority
MX
Mexico
Prior art keywords
diabetes
mhc
type
antigen
novel treatment
Prior art date
Application number
MX2024011668A
Other languages
English (en)
Spanish (es)
Inventor
Valentin Bruttel
Jörg Wischhusen
Daniela Brünnert
Fadhil Ahsan
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Publication of MX2024011668A publication Critical patent/MX2024011668A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
MX2024011668A 2022-03-24 2023-03-24 Inmunosupresion especifica del antigeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1. MX2024011668A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22164163 2022-03-24
PCT/EP2023/057681 WO2023180547A1 (en) 2022-03-24 2023-03-24 Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes

Publications (1)

Publication Number Publication Date
MX2024011668A true MX2024011668A (es) 2024-09-27

Family

ID=81327177

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011668A MX2024011668A (es) 2022-03-24 2023-03-24 Inmunosupresion especifica del antigeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1.

Country Status (12)

Country Link
US (1) US20250205323A1 (https=)
EP (1) EP4499133A1 (https=)
JP (1) JP2025510149A (https=)
KR (1) KR20240167684A (https=)
CN (1) CN118922202A (https=)
AU (1) AU2023238308A1 (https=)
CA (1) CA3255483A1 (https=)
CL (1) CL2024002839A1 (https=)
CO (1) CO2024012945A2 (https=)
IL (1) IL315756A (https=)
MX (1) MX2024011668A (https=)
WO (1) WO2023180547A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3400069A4 (en) * 2016-01-04 2019-09-25 Cour Pharmaceuticals Development Company Inc. Particles for the Encapsulation of Fusion Proteins with Bundled Epitopes
EP3630809A1 (en) 2017-05-23 2020-04-08 Bruttel, Valentin Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation

Also Published As

Publication number Publication date
WO2023180547A1 (en) 2023-09-28
EP4499133A1 (en) 2025-02-05
JP2025510149A (ja) 2025-04-14
IL315756A (en) 2024-11-01
CA3255483A1 (en) 2023-09-28
CO2024012945A2 (es) 2024-10-31
CN118922202A (zh) 2024-11-08
AU2023238308A1 (en) 2024-10-10
KR20240167684A (ko) 2024-11-27
CL2024002839A1 (es) 2025-02-21
US20250205323A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
SA521430398B1 (ar) Ph20 تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز البشرى، للحقن تحت الجلد
CN111148756A (zh) T细胞受体
ZA202104287B (en) Novel fusion proteins specific for cd137 and gpc3
RU2013114743A (ru) Композиции и способы для топического нанесения и трансдермальной доставки ботулинических токсинов
ES2671493T3 (es) Tratamiento con multiproteasa para el dolor crónico
EA039105B1 (ru) Катионные нейротоксины
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
ATE532795T1 (de) Tumor-assoziiertes peptid, welches an unterschiedliche menschliche leukozytenantigene der klasse ii bindet
PH12022500026A1 (en) Protease-activated t cell bispecific antibodies
AR128876A1 (es) Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
CA3234608A1 (en) Treatment of pain
MX2024011666A (es) Inmunosupresion especifica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo.
MX2024011665A (es) Induccion de tolerancia especifica de alfa-sinucleina mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson.
MX2024011668A (es) Inmunosupresion especifica del antigeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1.
WO2023180546A8 (en) Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease
BR112022022365A2 (pt) Peptídeo, anticorpo, receptor de células t, ácido nucleico, célula hospedeira recombinante, métodos in vitro para produzir linfócitos t ativados e para produzir uma vacina personalizada contra o câncer, linfócito t ativado, composição farmacêutica, e, kit
EE05293B1 (et) RG1 polpeptiidiga seonduv antikeha, seda h?lmav immunkonjugaat ja nende kasutamine
IL314832A (en) Hiv-specific binding molecules and tcr
JP2019531698A (ja) 活性化クロストリジウム神経毒の製造
BRPI0515893A (pt) peptìdeos da proteìna humana de estresse térmico, composição farmacêutica e método de tratamento da artrite reumatóide
MX2024004398A (es) Peptidos y fragmentos para tratar diabetes y enfermedades metabolicas asociadas.
MX2023002080A (es) Vector de poxviridae recombinante que expresa moleculas coestimuladoras.
WO2021158092A3 (ko) 보체 단백 분해 산물 c3a와 결합할 수 있는 신규한 폴리펩타이드 및 이의 용도
MX2025004937A (es) Proteínas de unión a subunidad gamma 1 auxiliar de canal activado por voltaje de calcio (cacng1) y administración mediada por cacng1 a músculo esquelético
Jimbow et al. Melanogenesis exploitation and melanoma nanomedicine: Utilization of melanogenesis substrate, NPrCAP for exploiting melanoma-targeting drug and its conjugation with magnetite nanoparticles for developing melanoma chemo-thermo-immunotherapy